Doctors sometimes use lithium to treat schizophrenia. However, it is not a primary treatment method and evidence of its ...
US poised to approve KarXT as new antipsychotic treatment for disorder, which could offer reduced side-effects ...
Cobenfy gives patients an alternative to drugs with troublesome side effects.
The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated ...
Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. BMO Capital analyst notes ...
The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...
The twice-daily pill, Cobenfy, is a badly needed new treatment option for the nearly 3 million adults in the U.S. living with ...
Formally known as KarXT, xanomeline-trospium chloride (Cobenfy) receives approval from the FDA for the treatment of ...
Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. Bristol-Myers added the ...
Spinogenix, the company behind the once-a-day pill that restored lost nerve cell connections in people with amyotrophic ...
On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...
People with schizophrenia will soon have a new treatment option after the FDA approved its first new treatment for the mental ...